Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc. reported a net loss of $16.6 million for fiscal year 2024, an improvement from a $20.0 million loss in the prior year. Revenue was minimal at $170K, down from $1.0 million in FY 2023, primarily from license agreements. Operating expenses totaled $18.4 million, with research and development costs of $7.9 million and general and administrative expenses of...